PT  - JOURNAL ARTICLE
AU  - Freyer, Gilles
AU  - Ray-Coquard, Isabelle
AU  - Fischer, Dorothea
AU  - Martín, Antonio González
AU  - Kielhorn, Adrian
AU  - Chia, Victoria
AU  - Nanayakkara, Nuwan
AU  - Taylor, Aliki
TI  - Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study
AID  - 10.1097/IGC.0000000000000590
DP  - 2016 Feb 01
TA  - International Journal of Gynecologic Cancer
PG  - 240--247
VI  - 26
IP  - 2
4099  - http://ijgc.bmj.com/content/26/2/240.short
4100  - http://ijgc.bmj.com/content/26/2/240.full
SO  - Int J Gynecol Cancer2016 Feb 01; 26
AB  - Objective Treatment options for patients with recurrent ovarian carcinoma are diverse, and different therapies are recommended based on platinum-free interval (PFI). Data examining the association between platinum sensitivity, treatment strategy, and outcomes are limited, particularly for partially platinum-sensitive (PPS) patients. This study characterized clinical features and outcomes in patients with recurrent ovarian carcinoma in the context of sensitivity to platinum-based therapy.Methods Anonymized case records were obtained from eligible European medical sites. Eligible patients were 18 years or older with epithelial ovarian carcinoma who had received 1 or more platinum-based therapies and had 1 or more subsequent relapses. Patient records were categorized by PFI and analyzed based on demographic and clinical data using descriptive statistics.Results There was no difference between PFI in PPS patients receiving platinum versus nonplatinum therapy (8.9 [range, 6.0–12.0] and 8.3 [range, 6.0–11.3] months, respectively). Overall survival in patients with platinum-sensitive, PPS, platinum-resistant, and platinum-refractory disease was 43.0 (95% confidence interval [95% CI], 25.1–42.3), 20.5 (95% CI, 17.7–24.8), 12.7 (95% CI, 10.4–14.2), and 9.8 (95% CI, 6.6–14.9) months, respectively. Among PPS patients, overall survival was 23.5 (95% CI, 18.4–37.3) and 18.7 (95% CI, 11.0–23.5) months for those who received platinum and nonplatinum-based therapy, respectively. No demographic or clinical characteristics were identified that indicated a difference between PPS patients who received platinum-based therapy versus those who did not.Conclusions Partially platinum-sensitive patients with recurrent ovarian carcinoma who received platinum-based therapy had improved outcomes compared with those who did not. No clear demographic criteria for choosing platinum- versus nonplatinum-based therapy for PPS patients were identified from patient records.